We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$546M
AUM Growth
+$63.4M
Cap. Flow
+$26M
Cap. Flow %
4.75%
Top 10 Hldgs %
90.77%
Holding
17
New
4
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$29.4M
2
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$14.2M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$12.1M
4
KRYS icon
Krystal Biotech
KRYS
+$10.5M
5
SYBX
Synlogic
SYBX
+$464K

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.7B
$231M 42.32%
2,316,447
– –
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
$92.4M 16.92%
3,190,079
– –
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$35.8M 6.55%
3,330,373
– –
GRTS
4
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$29.4M 5.38%
+2,061,762
New +$29.4M
COLL icon
5
Collegium Pharmaceutical
COLL
$820M
$27.8M 5.09%
1,887,332
– –
IOVA icon
6
Iovance Biotherapeutics
IOVA
$3.74B
$24.6M 4.51%
2,188,331
– –
ETTX
7
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$14.7M 2.69%
+1,349,953
New +$14.2M
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.9M 2.55%
2,199,011
– –
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$13.8M 2.53%
202,803
– –
SYBX
10
DELISTED
Synlogic
SYBX
$12.3M 2.25%
57,694
+2,929
+5% +$464K
NBRV
11
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$11.5M 2.1%
+17,026
New +$12.1M
KRYS icon
12
Krystal Biotech
KRYS
$10.6B
$11M 2.01%
+625,000
New +$10.5M
ITRM
13
DELISTED
Iterum Therapeutics
ITRM
$10.3M 1.89%
102,554
– –
BLCM
14
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$6.48M 1.19%
105,144
– –
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
$5.77M 1.06%
65,613
– –
KZR
16
DELISTED
Kezar Life Sciences
KZR
$5.35M 0.98%
25,000
– –
FOLD
17
DELISTED
Amicus Therapeutics
FOLD
– –
-2,600,014
Closed -$40.6M

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q3 2018 Portfolio in Review

As of Q3 2018, Frazier Management held 17 positions worth $546M, up 13% from $483M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Frazier Management deployed $26M of net new capital in Q3 2018, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Gritstone bio, Inc. Common Stock: 2,061,762 shares worth $29.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was Amicus Therapeutics, an estimated $40.6M sold.

  • Frazier Management's largest Q3 2018 buy was Gritstone bio, Inc. Common Stock: 2,061,762 shares worth $29.4M.
  • Frazier Management added most to Synlogic in Q3 2018, an estimated $464K increase.
  • Frazier Management fully exited Amicus Therapeutics in Q3 2018, selling an estimated $40.6M.
  • Frazier Management's ten largest holdings make up 91% of its $546M portfolio in Q3 2018.
  • Frazier Management opened 4 new positions and closed 1 in Q3 2018.
  • Frazier Management's portfolio value rose 13% quarter-over-quarter to $546M.

Based on Frazier Management's 13F filing for Q3 2018, filed 14 Nov 2018.